News & Views | Published:

CANCER IMMUNOTHERAPY

CAR T cells for childhood diffuse midline gliomas

Nature Medicinevolume 24pages534535 (2018) | Download Citation

Anti-GD2 chimeric antigen receptor (CAR)-modified T cells may be a new and innovative approach for the treatment of pediatric H3-K27M-mutant diffuse midline gliomas.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Jones, C. & Baker, S. J. Nat. Rev. Cancer 14, 651–661 (2014).

  2. 2.

    Mackay, A. et al. Cancer Cell 32, 520–537 (2017).

  3. 3.

    Lewis, P. W. et al. Science 340, 857–861 (2013).

  4. 4.

    Mount, C. W. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0006-x (2018).

  5. 5.

    Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).

  6. 6.

    Ahmed, N. et al. JAMA Oncol. 3, 1094–1101 (2017).

  7. 7.

    O’Rourke, D. M. et al. Sci. Transl. Med. 9, eaaa0984 (2017).

  8. 8.

    Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).

  9. 9.

    Yu, A. L. et al. N. Engl. J. Med. 363, 1324–1334 (2010).

  10. 10.

    Waligora, M. et al. PLoS Med. 15, e1002505 (2018).

  11. 11.

    Grasso, C. S. et al. Nat. Med. 21, 827 (2015).

Download references

Author information

Affiliations

  1. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada

    • Vijay Ramaswamy
  2. Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada

    • Michael D Taylor

Authors

  1. Search for Vijay Ramaswamy in:

  2. Search for Michael D Taylor in:

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Michael D Taylor.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41591-018-0031-9

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing